Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 6Tumor-Agnostic 5Gastrointestinal 5Breast 5Dermatologic 3Thoracic 2Head & Neck 2Gynecologic 2CNS 2Sarcoma 1Other solid neoplasm 1Genitourinary 1Classical hematology 1

Conditions

Melanoma 3Skin Neoplasms 1Neoplasm Metastasis 1

Interventions

pembrolizumab 326Nivolumab 289Ipilimumab 260Cyclophosphamide 193aldesleukin 145Interleukin-2 109fludarabine phosphate 106Temozolomide 83Dacarbazine 81fludarabine 80Radiotherapy 74trametinib 73Vemurafenib 69dabrafenib 66Biopsy 65sargramostim 50Bevacizumab 50Radiosurgery 49Paclitaxel 49Peripheral Blood Stem Cell Transplantation 48Carboplatin 48Magnetic Resonance Spectroscopy 47Imiquimod 47Aminolevulinic Acid 47binimetinib 45Cisplatin 45CTLA-4 Antigen 43cemiplimab 42atezolizumab 41Specimen Handling 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × reolysin × Dermatologic × Clear all
NCT03282188 2018-05-04

REO13 Melanoma With of Without GM-CSF

University of Leeds

Phase 1/2 Withdrawn
Dermatologic

Melanoma, Skin Neoplasms

NCT00984464 2015-04-10

Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

Oncolytics Biotech

Phase 2 Completed
14 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

NCT00651157 2014-04-22

Viral Therapy in Treating Patients With Metastatic Melanoma

National Cancer Institute (NCI)

Phase 2 Completed
23 enrolled 6 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡